Skip to main content

Sigma-Aldrich, SwitchGear Co-developing miRNA Target Validation System

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma-Aldrich and SwitchGear Genomics are partnering on a project to develop a novel microRNA target reporter system.

The collaboration announced today brings together SwitchGear's expertise and Sigma-Aldrich's lentiviral technology and is expected to result in a genome-wide collection of target vectors that will provide "highly effective miRNA target validation without the need for time-consuming and laborious reporter cloning," Sigma-Aldrich said in a statement.

Terms of the deal were not released.

According to Nathan Trinklein, CEO and co-founder of SwitchGear, the deal "will enable researchers to study miRNA function and gene regulation on an unprecedented scale."

Founded in 2005 by Stanford researchers, SwitchGear provides products for the study of regulatory elements in the human genome. In November, the Menlo Park, Calif.-based firm reached a deal with Promega to develop a new method for characterizing DNA-protein interactions.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.